Back buttonBack

Welcome to PEMAZYRE Denmark

This website is intended for healthcare professionals located in Denmark.

Please login:

Summary of Product Characteristics (SmPC) Read the compulsory Prescribing Information here
orange diamonds

What's on this site:

DNA helix

Mechanism of action

Histogram and magnifying glass

Efficacy

Shield and tick

Safety profile

Clock and pill

Dosing and administration schedule

Targeted medicine

FGFR2 fusion
testing

PEMAZYRE eDetail

Cholangiocarcinoma (CCA) & PEMAZYRE self-directed learning

A self-directed learning material to complete in your own time. With the learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.
orange diamonds
Medical book

FGFR2 fusion testing

Discover about FGFR2 fusions in patients with CCA

Incyteful Platform

Incyteful for you

An Incyte platform that offers medical education relevant to your daily practice. Easy to access, personalised content that fits with your schedule.

Incyteful is your one-stop resource for updates about the disease areas and Incyte's approved products that you care about.

Coming soon

External link disclaimer

Intended for licensed healthcare professionals located in Denmark.

You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event

Terms of Use Privacy Policy Cookie Policy
Report an adverse event Summary of Product Characteristics (SmPC) Prescribing Information

Marketing authorisation holder:
Incyte Biosciences Distribution B.V.
Paasheuvelweg 25
1105 BP Amsterdam
Netherlands

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local authority or to Incyte (by e-mail: eumedinfo@incyte.com).

DK/PEMA/P/22/0019
Date of preparation: June 2022
© 2022, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte.

If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/

External link disclaimer

Intended for licensed healthcare professionals located in Denmark.

You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event